期刊
CURRENT ONCOLOGY REPORTS
卷 23, 期 9, 页码 -出版社
SPRINGER
DOI: 10.1007/s11912-021-01094-y
关键词
Leukemic variant mantle cell lymphoma; Indolent mantle cell lymphoma; Non-nodal mantle cell lymphoma; TP53 mutation; Sox11 expression
类别
LV-MCL is a unique subtype of mantle cell lymphoma with distinct biological and clinical characteristics compared to classical MCL. Limited data exists on the treatment of LV-MCL, and many patients may have a clinically indolent course and do not require active treatment. Future prospective clinical trials are needed to optimize management strategies for LV-MCL.
Purpose of Review This review summarizes the unique presentation and management of the leukemic variant of mantle cell lymphoma (LV-MCL, also referred to as non-nodal MCL) and highlights the biologic and clinical differentiation from classical mantle cell lymphoma (cMCL) in biomarker expression, clinical features, prognosis, disease course, and treatment. Recent Findings Several studies have evaluated the gene expression profile of mantle cell lymphoma, differentiating LV-MCL from cMCL. The typical immunophenotypic profile is CD5-positive, SOX 11-negative, CD23-low, CD200-low, and cyclin D1 overexpressed. LV-MCL commonly has mutated immunoglobulin heavy chain variable region genes. Data on treatment of LV-MCL is limited to retrospective analyses; the ideal treatment for these patients is unknown although many have a clinically indolent, asymptomatic presentation and often may be observed for an extended period without active treatment. LV-MCL is a clinically and biologically distinct entity. Clinically, it must be distinguished from chronic lymphocytic leukemia and cMCL. Future prospective, randomized clinical trials are required to optimize management, define the initial treatment, and appropriately sequence treatment modalities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据